nach oben

Die Ophthalmologie

Erschienen in:

01.03.2005 | Medizin aktuell

Neue Erkenntnisse zu Erkrankungen der Augenoberfläche

Trockenes Auge, okuläre Allergie, infektiöse Konjunktivitis

verfasst von: Dr. E. M. Messmer, J. M. Benitez-del-Castillo, A. Lambiase, S. Doan

Erschienen in: Die Ophthalmologie | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Neue Erkenntnisse auf dem Gebiet des trockenen Auges, der okulären Allergie sowie der infektiösen Konjunktivitis beeinflussen unsere täglichen Therapieentscheidungen.

Anhand interessanter Beiträge auf der 76. Tagung der „Association for Research in Vision and Ophthalmology“ (ARVO), die vom 25. bis 29. April 2004 in Fort Lauderdale/FL, USA, stattfand, sollen im Folgenden neue Entwicklungen und mögliche therapeutische Konsequenzen dargestellt werden.

Abelson MB, Gomes PJ, Welch DL et al. (2004) Olopatadine 0.2% is effective for the once daily treatment of the ocular signs and symptoms associated with allergic conjunctivitis. Invest Ophthalmol Vis Sci ARVO E-Abstract 4824

Barber LD, Durham T, LaVange L et al. (2004) Effect of diquafosol on worst symptom of dry eye patients: focus on photophobia. Invest Ophthalmol Vis Sci ARVO E-Abstract 3914

Bonini S, Whitcup SM, Barrett J (2004) Efficacy of epinastine HCl 0.05% ophthalmic solution in patients with acute allergic conjunctivitis compared with ketotifen. Invest Ophthalmol Vis Sci ARVO E-Abstract 4842

Donnenfeld E, Perry H, Greenman H, Chruscicki D, Solomon R, Wittpenn J (2004) Ocular tolerability of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5%. Invest Ophthalmol Vis Sci ARVO E-Abstract 4925

Dua HS, Al-Abed M, Cade J, Shanmuganathan V, Gupta R, Tighe PJ, McIntosh RS (2004) The spectrum of expression of anti-microbial peptides at the ocular surface. Invest Ophthalmol Vis Sci ARVO E-Abstract 4933

Dursun D, Akova YA, Akca S et al. (2004) Smoking and ocular surface: damage on lipid layer? Invest Ophthalmol Vis Sci ARVO E-Abstract 97

Dvorak AW, John T, Clark J, Lyzak J (2004) In vitro susceptibilities of ocular isolates to old and new antibiotics. Invest Ophthalmol Vis Sci ARVO E-Abstract 4972

Farley WJ, Luo L, Chen LZ, Stern ME, Pflugfelder SC (2004) Effects of commercial 4thgeneration fluoroquinolones on corneal epithelial barrier function in experimental murine dry eye. Invest Ophthalmol Vis Sci ARVO E-Abstract 4904

Friedlaender MH, Shaft L, Breshears D (2004) Control of ocular allergy symptoms by epinastine HCl 0.05% in a conjunctival antigen challenge evaluation. Invest Ophthalmol Vis Sci ARVO E-Abstract 4841

10.

Gabler B, Fuchs B, Herrmann W et al. (2004) EGF supplement therapy with a controlled release device in patients with keratoconjunctivitis sicca seems to improve dry eye symptoms. Invest Ophthalmol Vis Sci ARVO E-Abstract 3910

11.

Gagnon J, Abelson MB, Pratt S, Fink K, Mussoline JF (2004) Measurement of allergic signs in a subjective versus objective manner for use in clinical trial evaluations. Invest Ophthalmol Vis Sci ARVO E-Abstract 52

12.

Gamache DA, McDonough TJ, Roberts L, Zhao L, Yanni JM (2004) Rimexolone dose-dependently inhibits corneal staining and increases tear breakup time in a rabbit model of lacrimal gland inflammation-induced dry eye. Invest Ophthalmol Vis Sci ARVO E-Abstract 62

13.

Greiner JV, Abelson MB, Gomes PJ et al. (2004) Olopatadine 0.2% reduces the primary sign and symptom of allergic conjunctivitis during peak pollen periods. Invest Ophthalmol Vis Sci ARVO E-Abstract 4854

14.

Hansen G, Hedlin P, Blondeau J (2004) The killing of ocular isolates of pseudomonas aeruginosa (PA) and klebsiella pneumoniae (KP) by gatifloxacin (GA)—a new fluoroquinolone (FQ). Invest Ophthalmol Vis Sci ARVO E-Abstract 4919

15.

Hedlin P, Blondeau J (2004) Comparative minimal inhibitory and mutant prevention concentration (MPC) of gatifloxacin (GA) and other compounds against gram-positive ocular pathogens. Invest Ophthalmol Vis Sci ARVO E-Abstract 4920

16.

Huang LC, Proske RJ, McDermott AM (2004) Functional roles of the epithelial-derived antimicrobial peptide LL-37 at the ocular surface. Invest Ophthalmol Vis Sci ARVO E-Abstract 4940

17.

Kossakiewicz MJ, Ta CN, He L, Klauss V, Blumenkranz MS, Miño de Kaspar H (2004) Antibiotic resistant pattern of conjunctival streptococci. Invest Ophthalmol Vis Sci ARVO E-Abstract 4001

18.

Levy NS, Friedlaender MH, Schachar RA (2004) Objective evaluation of ocular allergic reactions. Invest Ophthalmol Vis Sci ARVO E-Abstract 4840

19.

Mah FS, Romanowski EG, Yates KA, Kowalski RP, Gordon YJ (2004) Comparison of a new topical fluoroquinolone, gatifloxacin (zymar™), with levofloxacin (qixin™) and ciprofloxacin (ciloxan™) in the treatment of fluoroquinolone-resistant staphylococcus aureus keratitis in a NZW rabbit model. Invest Ophthalmol Vis Sci ARVO E-Abstract 4982

20.

Maissa C, Guillon M, Chamberlain P (2004) Effect of castor oil emulsion eyedrops on the tear film. Invest Ophthalmol Vis Sci ARVO E-Abstract 3900

21.

Narayanan S, Miller WL, McDermott AM (2004) Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest Ophthalmol Vis Sci ARVO E-Abstract 86

22.

Nell B, Walde I, Spiess BM et al. (2004) Exploratory study reveals topical pimecrolimus is active against keratoconjunctivitis sicca and chronic superficial keratitis in dogs. Invest Ophthalmol Vis Sci ARVO E-Abstract 131

23.

Ousler GW, Welch DW, Abelson MB (2004) Effect of menopause on blink rate in a population of dry eye patients when exposed to a controlled adverse environment (CAE). Invest Ophthalmol Vis Sci ARVO E-Abstract 80

24.

Parry P, Teale C, Irwin D, Burk C, Figueiredo M, Figueiredo F (2004) The clinical and quality of life outcomes of managing patients with keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci ARVO E-Abstract 3454

25.

Pauly A, Blondin C, Riancho L, Baudouin C (2004) Inhibition of histamine-induced human conjunctival cell release of pro-inflammatory cytokines IL-6 and IL-8. Invest Ophthalmol Vis Sci ARVO E-Abstract 4843

26.

Pollard S, Ousler III GW, Lipkin N, Abelson MB (2004) Dry eye quality of life questionnaire (DEQLQ^©)—outcome in a population of normals and patients diagnosed with dry eye. Invest Ophthalmol Vis Sci ARVO E-Abstract 82

27.

Rolando M, Scrimieri F, Mastromarino A, Amico V, Prigione G, Cro M, Giuffrida S (2004) Reduction of evaporative tear water loss from the ocular surface by means of a lipid containing tear substitute. Invest Ophthalmol Vis Sci ARVO E-Abstract 3877

28.

Rusinko A, May J, Liao J, Namil A, Hellberg M (2004) A study of the enhanced corneal penetration of moxifloxacin. Invest Ophthalmol Vis Sci ARVO E-Abstract 4907

29.

Sasanuma K, Yoshizaki S, Nakamura S, Saito F (2004) Suppression of tear fluid proinflammatory cytokines by d-3-hydroxybutyrate(HBA) in a rat dry eye model. Invest Ophthalmol Vis Sci ARVO E-Abstract 68

30.

Sheppard JD (2004) Diquafosol tetrasodium is effective in a broad spectrum of patients with dry eye. Invest Ophthalmol Vis Sci ARVO E-Abstract 3907

31.

Solomon R, Donnenfeld E, Perry H, Snyder R, Nedrud C, Stein J, Bloom A (2004) Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Invest Ophthalmol Vis Sci ARVO E-Abstract 4928

32.

Stern ME, Siemasko KF, Gao J et al. (2004) The role of IFN-γ in the pathophysiology of T_H2 inflammation in the mouse model of allergic conjunctivitis. Invest Ophthalmol Vis Sci ARVO E-Abstract 1503

33.

Toda I, Kamiyama Y, Sakai C, Goto E, Tsubota K (2004) Efficacy of disposable eyelid warming device for the treatment of post-LASIK dry eye. Invest Ophthalmol Vis Sci ARVO E-Abstract 186

34.

Tsubota K, Mishima K, Saito I (2004) Identification of side population cells in lacrimal glands for the novel cell therapy of dry eye. Invest Ophthalmol Vis Sci ARVO E-Abstract 3872

35.

Wang J, Hussaini IM, Laurie GW (2004) Lacrimal/salivary prosecretory mitogen „lacritin“ as a glandular stem cell survival factor. Invest Ophthalmol Vis Sci ARVO E-Abstract 3885

36.

Wilcox KA, Ousler GW, Welch DW, Abelson MB (2004) Effect of menopause on the ocular protection index (OPI) in a population of dry eye patients. Invest Ophthalmol Vis Sci ARVO E-Abstract 79

Titel: Neue Erkenntnisse zu Erkrankungen der Augenoberfläche
Trockenes Auge, okuläre Allergie, infektiöse Konjunktivitis
verfasst von: Dr. E. M. Messmer
J. M. Benitez-del-Castillo
A. Lambiase
S. Doan
Publikationsdatum: 01.03.2005
Verlag: Springer-Verlag
Erschienen in: Die Ophthalmologie / Ausgabe 3/2005
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-004-1153-7

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Neue Erkenntnisse zu Erkrankungen der Augenoberfläche

Trockenes Auge, okuläre Allergie, infektiöse Konjunktivitis

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Transkonjunktivale Botulinumtoxininjektion zur Behandlung der Oberlidretraktion bei endokriner Orbitopathie

Ergebnisse der „Collaborative Initial Glaucoma Treatment Study“ (CIGTS)

Fundus hypertonicus

Screening der diabetischen Retinopathie und Papillentopographie mit dem „Retinal Thickness Analyzer“ (RTA)

Sekundärglaukom bei Hyphäma, Hypopyon, Irisprominenz und Irishyperämie

Einjahresergebnisse nach LASEK

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde